The package of tax reforms expected to be signed into law includes several provisions that will impact some people with cystic fibrosis.
- Health Care Reform
- Our Advocacy Work
- Get Involved
- About the CF Foundation
- Drug Pipeline
- Patient Assistance
- CFTR Modulators
- In the Spotlight
- Clinical Trials
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- In Memoriam
- North American CF Conference
- Our Research Approach
- Researcher Resources
A group of nonpartisan patient and consumer organizations issued a statement after passage of the Tax Cuts and Jobs Act.
The Cystic Fibrosis Foundation's Greater New York Chapter recently recognized leading journalist Scott Pelley at the 14th annual Breath of Life Gala for his unwavering dedication to those living with CF.
This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.
Bonnee Binker and Paul Motenko to lead efforts in Washington, D.C., for volunteer conference, teamMATEs: Together Until It's Done.
Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
As the Senate considers adding repeal of the Affordable Care Act's (ACA) individual mandate to its tax reform package, a group of 16 nonpartisan patient and consumer groups issued a statement on last week's Congressional Budget Office (CBO) report.
The Cystic Fibrosis Foundation awarded U.S. Sen. Susan Collins (R-Maine) the Breath of Life Legislator Award on Nov. 3 for her leadership in ensuring that people with cystic fibrosis have access to the adequate, affordable care they need to live full and healthy lives.
The 23rd annual Ultimate Golf Experience (UGE) brought together a star-studded lineup of entertainers and friends, who gathered in Newport Coast, Calif. to raise funds in the fight against cystic fibrosis.
The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of lumacaftor/ivacaftor (Orkambi®) and ivacaftor/tezacaftor (VX-661). The Foundation is sharing input throughout the process to help incorporate the patient and clinical perspective.